BioStem Technologies Inc(BSEM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | 31.8% | Shs Outstand | 17.8M | Perf Week | -18.63% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | 45.26% | Insider Trans | - | Shs Float | 12.7M | Perf Month | -56.32% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.43 | Inst Own | - | Short Float | 0.77% | Perf Quarter | -58.6% |
| Income | -0.03B | P/S | 0.9 | EPS this Y | -387.18% | Inst Trans | 0.04% | Short Ratio | 0.73 | Perf Half Y | -62.7% |
| Sales | 0.03B | P/B | 1.07 | EPS next 5Y | 38.66% | ROA | -35.05% | Short Interest | 0.10M | Perf YTD | -56.43% |
| Book/sh | 1.55 | P/C | 4.45 | EPS past 3/5Y | 14.56% -7.36% | ROE | -74.74% | 52W High | -80.24% ($8.40) | Perf Year | -66.05% |
| Cash/sh | 0.37 | P/FCF | - | Sales past 3/5Y | 90.44% 81.44% | ROIC | -102.44% | 52W Low | 14.48% ($1.45) | Perf 3Y | -55.26% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -204.26% | Gross Margin | 76.08% | Volatility(W/M) | 19.38% 13.74% | Perf 5Y | 15.28% |
| Dividend TTM | - | EV/Sales | 0.73 | Sales Y/Y TTM | -88.74% | Oper. Margin | -67.47% | ATR (14) | 0.34 | Perf 10Y | -77.87% |
| Dividend Ex-Date | - | Quick Ratio | 0.76 | EPS Q/Q | -1431.95% | Profit Margin | -81.8% | RSI (14) | 27.81 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.98 | Sales Q/Q | -83.98% | SMA20 | -35.01% ($2.55) | Beta | 0.58 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/12 | SMA50 | -49.72% ($3.3) | Rel Volume | 0.37 | Prev Close | $1.68 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | -4% 24.36% | SMA200 | -61.4% ($4.3) | Avg Volume(3M) | 0.14M | Price | $1.66 |
| IPO | 2003/10/17 | Option/Short | No/Yes | Trades | 310 | Volume | 49,620 | Change | -1.19% |
A US-based life sciences company that develops and manufactures regenerative medicine products derived from placental tissue. It supplies allograft implants—produced using its proprietary processing technology—to the chronic wound care market, and has steadily expanded its applications into tissue regeneration areas where healing tends to be slow, including damage to joints, tendons, and ligaments.
Over the past 1 year, on the lower side
80% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
BSEM has weak earning power
Of every $100 in sales, $67.47 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -387.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $90. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be +15.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
It ranks #449 of 594 in the industry
Based on market cap of $31M.
ESLA#447 Estrella Immunopharma Inc $32M PER - 
FLNA#448 Filana Therapeutics Inc $32M PER - BSEM#449 BioStem Technologies Inc $31M PER - 
EVAX#450 Evaxion A/S ADR $31M PER - 
MGX#451 Metagenomi Therapeutics Inc $31M PER - 
FAQ
What kind of company is BSEM?
BSEM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BSEM?
The market cap of BSEM is approximately $31M, ranking 5,082 within its sector.
What is the 52-week high and low for BSEM?
BSEM has recorded a 52-week high of $8.40 and a low of $1.45.
